老年非霍奇金淋巴瘤患者潜在不适当用药与生存率降低及毒性增加相关。
Potentially inappropriate medication use in elderly non-Hodgkin lymphoma patients is associated with reduced survival and increased toxicities.
作者信息
Lin Richard J, Ma Helen, Guo Robin, Troxel Andrea B, Diefenbach Catherine S
机构信息
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Division of Hematology and Medical Oncology, Laura & Isaac Perlmutter Cancer Center at New York University Langone Medical Center, New York, NY, USA.
出版信息
Br J Haematol. 2018 Jan;180(2):267-270. doi: 10.1111/bjh.15027. Epub 2017 Nov 16.
Abstract
Survival outcomes for elderly lymphoma patients are disproportionally inferior to those of younger patients. We examined medication usage at diagnosis for 171 elderly patients (median age 70 years) with aggressive non-Hodgkin lymphoma treated between 2009 and 2014. At least one potentially inappropriate medication was used in 47% of patients according to the Beers Criteria, 59% experienced treatment delays and/or dose reduction and 65% experienced ≥ grade 3 treatment-related toxicities. We report here for the first time that potentially inappropriate medication use was associated with reduced progression-free survival and overall survival, and increased ≥ grade 3 treatment-related toxicities in multivariate analysis.
摘要
老年淋巴瘤患者的生存结果相较于年轻患者要差得多。我们研究了2009年至2014年间接受治疗的171例老年（中位年龄70岁）侵袭性非霍奇金淋巴瘤患者在诊断时的用药情况。根据Beers标准，47%的患者至少使用了一种潜在不适当药物，59%的患者经历了治疗延迟和/或剂量减少，65%的患者经历了≥3级治疗相关毒性。我们首次在此报告，在多变量分析中，潜在不适当药物的使用与无进展生存期和总生存期缩短以及≥3级治疗相关毒性增加有关。
相似文献
1
Potentially inappropriate medication use in elderly non-Hodgkin lymphoma patients is associated with reduced survival and increased toxicities.老年非霍奇金淋巴瘤患者潜在不适当用药与生存率降低及毒性增加相关。
Br J Haematol. 2018 Jan;180(2):267-270. doi: 10.1111/bjh.15027. Epub 2017 Nov 16.
2
Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611).新型药物在老年慢性淋巴细胞白血病和非霍奇金淋巴瘤患者中导致三级或四级毒性的频率和影响（alliance A151611）。
J Geriatr Oncol. 2018 Jul;9(4):321-328. doi: 10.1016/j.jgo.2018.03.018. Epub 2018 Apr 17.
3
Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome.80岁以上高龄患者的非霍奇金淋巴瘤。临床表现及预后的描述性分析。
Ann Oncol. 2008 Apr;19(4):774-9. doi: 10.1093/annonc/mdm563. Epub 2007 Dec 6.
4
Clinical Outcomes, Treatment Toxicity, and Health Care Utilization in Older Adults with Aggressive Non-Hodgkin Lymphoma.老年侵袭性非霍奇金淋巴瘤患者的临床结局、治疗毒性和医疗保健利用情况。
Oncologist. 2021 Nov;26(11):965-973. doi: 10.1002/onco.13915. Epub 2021 Aug 12.
5
Obese non-Hodgkin lymphoma patients tolerate full uncapped doses of chemotherapy with no increase in toxicity, and a similar survival to that seen in nonobese patients.肥胖的非霍奇金淋巴瘤患者能够耐受全量无限制剂量的化疗，且毒性不增加，生存情况与非肥胖患者相似。
Leuk Lymphoma. 2016 Nov;57(11):2584-92. doi: 10.3109/10428194.2016.1151508. Epub 2016 Mar 4.
6
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.利妥昔单抗：用于非霍奇金淋巴瘤和慢性淋巴细胞白血病的综述
Drugs. 2003;63(8):803-43. doi: 10.2165/00003495-200363080-00005.
7
Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma.淋巴瘤和HIV特异性因素对艾滋病相关非霍奇金淋巴瘤预后影响的变化
Ann Oncol. 2015 May;26(5):958-966. doi: 10.1093/annonc/mdv036. Epub 2015 Jan 28.
8
MTX-HOPE is a low-dose salvage chemotherapy for aged patients with relapsed or refractory non-Hodgkin lymphoma.MTX-HOPE 是一种低剂量挽救化疗方案，适用于复发或难治性非霍奇金淋巴瘤的老年患者。
J Clin Exp Hematop. 2021 Mar 18;61(1):22-28. doi: 10.3960/jslrt.20051. Epub 2021 Feb 6.
9
Potentially inappropriate medication use in older patients with breast and colorectal cancer.老年乳腺癌和结直肠癌患者潜在不适当药物使用。
Cancer. 2018 Jul 15;124(14):3000-3007. doi: 10.1002/cncr.31403. Epub 2018 Apr 24.
10
[Prognostic impact of anthracyclines in the treatment of aggressive lymphoma in patients over 70 years].[蒽环类药物对70岁以上侵袭性淋巴瘤患者治疗的预后影响]
Med Clin (Barc). 2015 Jun 22;144(12):544-7. doi: 10.1016/j.medcli.2014.04.026. Epub 2014 Aug 8.
引用本文的文献
1
Association of potentially inappropriate medications with prognosis among older patients with non-small cell lung cancer.可能不适当的药物与老年非小细胞肺癌患者预后的关联。
BMC Geriatr. 2024 Jun 25;24(1):550. doi: 10.1186/s12877-024-05138-3.
2
Association of Polypharmacy and Potentially Inappropriate Medications With Frailty Among Older Adults With Blood Cancers.血液癌症老年患者药物滥用和潜在不适当药物与虚弱的关系。
J Natl Compr Canc Netw. 2022 Aug;20(8):915-923.e5. doi: 10.6004/jnccn.2022.7033.
3
Use of Potentially Inappropriate Medications in Older Allogeneic Hematopoietic Cell Transplantation Recipients.老年异基因造血细胞移植受者潜在不适当药物的使用。
Biol Blood Marrow Transplant. 2020 Dec;26(12):2329-2334. doi: 10.1016/j.bbmt.2020.08.031. Epub 2020 Sep 10.
4
Prevalence and effects of polypharmacy on overall survival in acute myeloid leukemia.在急性髓系白血病中，多种药物治疗的流行情况及其对总生存率的影响。
Leuk Lymphoma. 2020 Jul;61(7):1702-1708. doi: 10.1080/10428194.2020.1737687. Epub 2020 Mar 11.
5
Prevalence and factors associated with potentially inappropriate medication use in older medicare beneficiaries with cancer.癌症老年医疗保险受益人群中潜在不适当药物使用的流行情况及相关因素。
Res Social Adm Pharm. 2020 Oct;16(10):1459-1471. doi: 10.1016/j.sapharm.2019.12.018. Epub 2019 Dec 26.
6
Associations of Polypharmacy and Inappropriate Medications with Adverse Outcomes in Older Adults with Cancer: A Systematic Review and Meta-Analysis.多药治疗和不适当药物与老年癌症患者不良结局的关联：系统评价和荟萃分析。
Oncologist. 2020 Jan;25(1):e94-e108. doi: 10.1634/theoncologist.2019-0406. Epub 2019 Sep 30.
7
Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adults.老年患者异基因造血细胞移植后多因素老年综合征的负担和影响。
Blood Adv. 2019 Jan 8;3(1):12-20. doi: 10.1182/bloodadvances.2018028241.
本文引用的文献
1
Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma.蒽环类药物及综合老年评估在老年弥漫性大B细胞淋巴瘤患者中的作用
Blood. 2017 Nov 16;130(20):2180-2185. doi: 10.1182/blood-2017-05-736975. Epub 2017 Aug 16.
2
Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.老年人弥漫性大 B 细胞淋巴瘤：标准治疗与新视角。
Expert Rev Hematol. 2017 Apr;10(4):289-297. doi: 10.1080/17474086.2017.1305264. Epub 2017 Mar 27.
3
Polypharmacy and potentially inappropriate medication use in geriatric oncology.老年肿瘤患者的多种药物治疗和潜在不适当药物使用。
J Geriatr Oncol. 2016 Sep;7(5):346-53. doi: 10.1016/j.jgo.2016.07.010. Epub 2016 Aug 3.
4
Chemotherapy-related cognitive impairment in older patients with cancer.癌症老年患者的化疗相关认知障碍。
J Geriatr Oncol. 2016 Jul;7(4):270-80. doi: 10.1016/j.jgo.2016.04.008. Epub 2016 Jul 5.
5
Comprehensive geriatric assessment in elderly patients with newly diagnosed aggressive non-Hodgkin lymphoma treated with multi-agent chemotherapy.对新诊断的侵袭性非霍奇金淋巴瘤老年患者进行多药化疗时的综合老年评估。
J Geriatr Oncol. 2015 Nov;6(6):470-8. doi: 10.1016/j.jgo.2015.10.183. Epub 2015 Oct 27.
6
American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.美国老年医学会2015年更新的《老年人潜在不适当用药的Beers标准》
J Am Geriatr Soc. 2015 Nov;63(11):2227-46. doi: 10.1111/jgs.13702. Epub 2015 Oct 8.
7
Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer.评估药剂师主导的药物评估，以确定患有癌症的门诊老年患者中药物使用过多和潜在不适当用药的流行程度和相关因素。
J Clin Oncol. 2015 May 1;33(13):1453-9. doi: 10.1200/JCO.2014.58.7550. Epub 2015 Mar 23.
8
Reducing inappropriate polypharmacy: the process of deprescribing.减少不适当的多种药物治疗：减药过程。
JAMA Intern Med. 2015 May;175(5):827-34. doi: 10.1001/jamainternmed.2015.0324.
9
Impact of comorbidities on the treatment of non-Hodgkin's lymphoma: a systematic review.合并症对非霍奇金淋巴瘤治疗的影响：一项系统综述
Expert Rev Hematol. 2015 Jun;8(3):329-41. doi: 10.1586/17474086.2015.1024650. Epub 2015 Mar 16.
10
Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary.老年弥漫性大 B 细胞淋巴瘤的治疗方法：国际老年肿瘤学会（SIOG）专家立场评论。
Ann Oncol. 2015 Jun;26(6):1058-1068. doi: 10.1093/annonc/mdv018. Epub 2015 Jan 29.
Zotero 插件